

Peripheral inflammatory response in human tuberculosis treatment is predicted by a combination of pathogen sterilization and microbiome dysbiosis

Matthew F. Wiperman^{1,2,#}, Shakti K. Bhattarai^{3,#}, Charles Kyriakos Vorkas^{1,4}, Ying Taur⁵, Laurent Mathurin⁶, Katherine McAulay⁷, Stalz Charles Vilbrun⁶, Daphie Jean Francois¹¹, James Bean¹, Kathleen F. Walsh⁷, Carl Nathan⁸, Daniel W. Fitzgerald⁷, Michael S. Glickman^{1,4,8,*}, Vanni Bucci^{3,9,10,*}

Affiliations:

¹ Immunology Program, Sloan Kettering Institute

² Clinical and Translational Science Center, Weill Cornell Medicine

³ Department of Microbiology and Physiological Systems, University of Massachusetts Medical School

⁴ Division of Infectious Diseases, Weill Cornell Medicine

⁵ Division of Infectious Diseases, Memorial Sloan Kettering Cancer Center

⁶ Haitian Study Group for Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti

⁷ Center for Global Health, Weill Cornell Medicine

⁸ Immunology and Microbial Pathogenesis Graduate Program, Weill Cornell Graduate School

⁹ Center for Microbiome Research, University of Massachusetts Medical School

¹⁰ Program in Systems Biology, University of Massachusetts Medical School

¹¹ Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, USA

these authors contributed equally

*Correspondence to:

Vanni Bucci, PhD

Microbiology and Physiological Systems

Program in Systems Biology

Center for Microbiome Research

University of Massachusetts Medical School

368 Plantation Street

Worcester, MA 01605

774-856-2215

vanni.bucci2@umassmed.edu

Michael S. Glickman MD

Immunology Program, Sloan Kettering Institute

1275 York Ave

New York, NY 10065

6468882368

glickmam@mskcc.org

42 **Abstract**

43 Antibiotic therapy cures infection predominantly by killing the infecting pathogen, but for infections such as
44 tuberculosis (TB), which are accompanied by chronic inflammation, the salutary effects of antibiotic therapy
45 may reflect a combination of pathogen killing and microbiome alteration. This question has not been examined
46 in humans due to the difficulty in dissociating the immunologic effects of antibiotic induced pathogen clearance
47 and microbiome alteration. We analyzed sputum TB bacterial load, microbiome composition, and peripheral
48 blood transcriptomics from a clinical trial (NCT02684240) comparing two antimicrobial therapies for
49 tuberculosis, only one of which was clinically effective. We confirm that standard TB therapy (HRZE) rapidly
50 depletes Clostridia from the intestinal microbiota. The antiparasitic drug nitazoxanide (NTZ), although
51 ineffective in reducing *Mycobacterium tuberculosis* (*Mtb*) bacterial load in the sputum, caused profound
52 alterations to host microbiome composition overlapping with alterations generated by HRZE. We then evaluated
53 the effect of these two treatments on the TB driven inflammatory state and found that whereas HRZE
54 normalized proinflammatory TB-associated gene sets, NTZ exacerbated these pathways. Using Random Forest
55 Regression, we identify both pathogen sterilization and microbiome disruption as the top predictors of changes
56 in TB-associated inflammatory transcriptomic markers. We then validate the observed microbiome-peripheral
57 gene expression associations in an independent human cohort of healthy subjects in which the abundance of
58 Clostridia was positively associated with homeostatic, and negatively associated with pro-inflammatory
59 pathways, while the abundance of Bacilli and Proteobacteria species displayed the opposite trend. Our findings
60 indicate that antibiotic-induced reduction in pathogen burden and changes in the microbiome are
61 independently associated with treatment-induced changes of the inflammatory response of active TB, and more
62 broadly indicate that response to antibiotic therapy may be a combined effect of pathogen killing and
63 microbiome driven immunomodulation. Additionally, to our knowledge, this is the first analysis to directly test
64 the hypothesis that the microbiome composition is associated with peripheral gene expression inflammatory
65 profile in humans.

66

67 Introduction

68 There is mounting evidence that the gut microbiome has an important role in the modulation of host physiology,
69 with a wealth of studies having associated microbiome composition and functions with differential
70 inflammatory, neurological, and even behavioral activity¹. Gastrointestinal colonization by specific taxa with
71 particular metabolic capacities has been shown to differentially modulate host biology². For example,
72 colonization by a subset of Clostridia enhanced anti-inflammatory phenotypes in mice³, and enrichment in
73 specific members of the *Bacteroides* and *Parabacteroides* genera induced CD8+ T cell responses and anticancer
74 activity in mice and marmosets⁴, as well as correlating with the abundance of these immune effectors in
75 humans⁵. A multitude of experiments in mice have allowed for the determination of mechanisms by which
76 intestinal mucosal-associated bacteria affect host physiology at the epithelial interface and systemically
77 throughout their host^{6,7}.

78
79 Despite these observations, it is unknown whether, and to what degree, microbiome changes are responsible
80 for changes in human systemic inflammatory responses. This knowledge gap is due in part to the difficulty of
81 isolating the microbiome dependent effects from other aspects of human physiology and in discerning the
82 direction of causality in human studies. As microbial communities in the gut promote the development and
83 maintenance of innate and adaptive immune responses, including microbiota-educated immune cells and many
84 small molecules that circulate throughout the periphery, we would expect to observe both localized and
85 systemic host effects due to microbiome alterations⁸.

86
87 Infection by *Mycobacterium tuberculosis* (*Mtb*) is the cause of tuberculosis (TB) disease—the 9th leading cause
88 of death on Earth⁹. A plethora of studies using whole blood transcriptomics have documented that individuals
89 with active TB display a different systemic gene expression pattern compared to people with latent disease,
90 other respiratory diseases, or no known infection⁹⁻¹¹. Specifically, infection with *Mtb* leads to heightened
91 expression of inflammatory pathways, most notably the Type I and Type II interferon pathways¹²⁻¹⁵, and this
92 pattern resolves with antibiotic therapy^{12,15,16}. A recent meta-analysis combining microarray and RNAseq data
93 from studies aimed at identify active TB transcriptional signatures confirmed the findings about a specific set of
94 peripheral blood transcripts that are biomarkers of active TB disease, relative to healthy individual, or those
95 with latent TB infection (LTBI)¹⁷.

96
97 Antibiotic treatment for active TB involves combination therapy with narrow spectrum and prodrug agents with
98 mostly *Mycobacterial*-specific targets. The World Health Organization guidelines for treating infection with drug

99 sensitive *Mtb* are to give isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E) (HRZE) for two months
100 and then to continue HR for an additional four months. The effects of HRZE therapy on the intestinal microbiome
101 were demonstrated in a longitudinal study in mice¹⁸ and cross-sectional study in humans¹⁹, which indicated that
102 the major phyla perturbed are from the class Clostridia, a group of obligate anaerobes in the gut with well
103 described immunomodulatory effects on the host^{2,3,20,21}. Given that HRZE treatment causes microbiome shifts
104 that include the depletion of many Clostridia species, and given the role that these species play in modulation
105 of host biology in mice and humans, we reasoned that there could be a connection between the microbiome
106 alterations observed during HRZE therapy and the resolution of systemic inflammatory responses to TB.
107 However, because HRZE therapy rapidly reduces the burden of *Mtb* in the early phase of treatment, it is difficult
108 to uncouple the immunologic effects of pathogen killing from microbiome perturbation without a control group
109 that has either pathogen killing or microbiome perturbation, but not both.


110
111 An opportunity to address this issue arose when we analyzed secondary endpoint data from a clinical trial
112 (NCT02684240) that compared the early bactericidal effect (EBA) of standard TB therapy with HRZE to the
113 antiparasitic drug nitazoxanide (NTZ), recently shown to possess antimycobacterial activity *in vitro*^{22,23}. We
114 found that NTZ perturbed the intestinal microbiome, with pathobiont domination and Clostridia depletion. This
115 contrasted with HRZE treatment, which had a narrow effect on intestinal Clostridia after only two weeks of
116 treatment. We then found that HRZE and NTZ had distinct effects on host peripheral gene expression, with HRZE
117 resolving interferon signatures and NTZ exacerbating them. We used machine learning to determine the factors
118 that predict correction or exacerbation of TB associated systemic inflammation and found that the three most
119 important predictors are (a) the *Mtb* level in the sputum, (b) the abundance of Clostridia species that associate
120 with inflammatory renormalization, and (c) the abundance of antibiotic-promoted Proteobacteria that associate
121 with exacerbation of proinflammatory pathways. We next investigated these relationships using a validation
122 cohort of healthy Haitian community controls and household contacts of TB patients, previously described⁵.
123 Using machine learning to investigate relationships between the microbiome and peripheral gene pathways
124 derived from the MiSigDB hallmark gene pathways database, we validated many of the relationships between
125 peripheral gene expression and microbiome composition. We believe these results provide support to the oft
126 stated hypothesis that there exists clear regulatory relationships between gut microbiome composition and
127 peripheral composition, at both the immune⁵, and gene regulatory levels in humans.

129 Results

130 Gut microbiome diversity is depleted after two weeks of HRZE or NTZ treatment

131 As detailed elsewhere, the GHESKIO centers in Port au Prince, Haiti conducted a prospective, randomized, early
132 bactericidal activity (EBA) study in treatment-naive, drug-susceptible adult patients with uncomplicated
133 pulmonary tuberculosis (TB) (ClinicalTrials.gov Identifier: NCT02684240)²³. Participants were randomized to
134 receive either NTZ, 1000 mg po (oral) twice daily, or standard oral therapy with isoniazid 300 mg daily, rifampin
135 600 mg daily, pyrazinamide 25 mg/kg daily, and ethambutol 15 mg/kg daily (referred to as HRZE) for 14 days
136 (Figure 1A). The primary endpoint of the trial was sputum bacterial load (measured by time to culture positivity,
137 TTP) in a BACTEC liquid culture system. Sputum was collected from 6pm to 9am every other day to quantify
138 mycobactericidal activity of each treatment regimen. As reported²³, HRZE resulted in a predictable increase in
139 the TTP (corresponding to reduced bacterial load) over the first two weeks of therapy compared to pretreatment
140 TTP, consistent with its known potent bactericidal activity. However, NTZ, despite potent in vitro activity²⁴, did
141 not have any significant effect on TTP after 14 days (Figure 1B)²³. This lack of NTZ efficacy was traced to a failure
142 of the drug to penetrate the sputum²³. All patients were subsequently switched to HRZE standard treatment.

143
144 We have reported¹⁹ that HRZE therapy depletes members of the order Clostridiales, but the cross-sectional
145 design of that study did not allow for conclusions about the rapidity of this effect and most importantly, did not
146 include pretreatment samples that will allow for assessment of baseline microbiome composition. To investigate
147 microbiome changes induced by NTZ or HRZE, we extracted and amplified bacterial and archaeal DNA using V4
148 – V5 16S rDNA sequencing. Stool samples were collected before the start of treatment and on day 14 of therapy
149 (Figure 1A). Using principal components analysis (PCoA) with Bray Curtis distances, we determined that
150 antibiotic administration induced rapid changes in microbiome community structure after two weeks in both
151 the NTZ and HRZE groups (PERMANOVA: $p < 0.001$ and $p < 0.02$, respectively), compared with pretreatment
152 (Figure 1C). HRZE samples clustered closer to pretreatment samples than did NTZ to pretreatment. Both
153 treatments were characterized by a significant drop in alpha diversity (the Inverse Simpson index) when
154 compared to pretreatment samples, and despite expected interindividual heterogeneity, NTZ treatment
155 samples had a significantly lower diversity compared to HRZE (Figure 1C). There was no significant difference
156 between the day 0 diversity metrics between the pre-randomized active TB groups (Figure 1D).



157

158

159

160

161

162

163

164


165

Figure 1: Both HRZE and NTZ perturb the gut microbiome after two weeks of therapy. **A.** Schematic showing active TB patients randomized to either HRZE (standard of care) or NTZ. **B.** Paired time to positivity (TTP) at day 0 and day 14 for the NTZ treatment cohort and HRZE treatment cohort. **C.** Principal components analysis (PCoA) with Bray-Curtis distance showing differences in microbiome community structure between individuals before and after 14 days of either HRZE or NTZ treatment. The grey line connects pre and day 14 treatment paired samples. **D.** Microbiota alpha diversity plotted using the Inverse Simpson index. There was no significant difference between the pretreatment groups, and both groups had significantly ($p < 0.01$, Wilcoxon signed-rank test) reduced alpha diversity after 14 days of treatment.

166 **Overlapping taxonomic alterations in microbiome composition induced by NTZ and HRZE**

167 Taxonomic profiling of differential amplicon sequence variants (ASVs) obtained from the 16S rDNA profiling
168 between the pretreatment and antibiotic groups revealed that, whereas all trial participants began with typical
169 heterogeneous community structure, after two weeks of treatment with HRZE, members of the class Clostridia
170 were depleted, leaving most other clades unaltered (Figure 2A,B). In contrast, NTZ had a much more pronounced
171 and broad effect compared to HRZE (Figure 2A,C). Specifically, NTZ not only reduced the relative abundance of
172 a greater number of Clostridia compared to HRZE, but also led to the increase of aerobic and facultative
173 anaerobic pathobiont organisms such as *Escherichia* and *Klebsiella* (Proteobacteria). Additionally, several
174 participants became dominated (with domination defined as >30% relative abundance according to Taur, et al²⁵)
175 by single clades of *Actinobacteria* or *Bacilli* in the NTZ arm of the trial (Figure 2A,C and Supplementary Figure S1
176 and S2).

177
178 Comparison of the overlap of the two antibiotic perturbations with respect to number of Clostridia genera
179 affected (i.e., testing for differences pre-post HRZE/NTZ administration on bacterial abundances grouped at the
180 genus level) revealed that 83% (10/12) of the HRZE-depleted Clostridia were also depleted by NTZ (Figure 2D).
181 HRZE uniquely affected Clostridia genera *Acutalibacter* and *Hespellia*, whereas NTZ affected 22 unique Clostridia
182 genera, including *Blautia*, *Dorea*, *Eubacterium*, *Faecalibacterium*, *Oscillibacter*, *Ruminococcus*, and
183 *Lachnospiraceae*. Both treatments affected the genera *Clostridium*, *Fusicatenibacter*, *Hungatella*,
184 *Intestinibacter*, *Intestinimonas*, *Kineothrix*, *Roseburia*, *Sporobacter*, *Terrisporobacter*, and an uncultured
185 member of the Family *Ruminococcaceae*. Taken together, these data demonstrate that NTZ had a more severe
186 disruptive effect on the intestinal microbiota than HRZE and that most of the HRZE effects on the microbiota
187 (e.g. loss of Class Clostridia) were also evident in NTZ treated subjects.



188

189

190

191

192

193

194

195

Figure 2: Overlapping and distinct microbiome perturbation induced by NTZ and HRZE. **A.** Relative abundance showing microbiota composition in each individual patient as stacked paired samples corresponding to pre and post treatment. Only paired samples were used for these analyses. **B.** Unsupervised hierarchical clustering of the abundances of ASVs identified to be significantly affected by HRZE treatment ($p < 0.01$); VST indicates variance stabilized transformed counts from DESeq2. **C.** Unsupervised hierarchical clustering of the abundances of ASVs identified to be significantly affected by NTZ treatment ($p < 0.01$). **D.** Number of Clostridia genera depleted (i.e. reduced in relative abundance) by HRZE and NTZ treatment.

196 **HRZE and NTZ uniquely affect host peripheral gene expression**

197 To determine how inflammatory transcriptional signatures in peripheral blood are affected by TB treatment, we
198 applied unsupervised (PCA) and supervised learning (Support Vector Machine and Random Forest Classification)
199 methods to the DESeq-normalized RNA transcript abundances from RNA derived from peripheral blood
200 (Supplementary Figure S3). This analysis showed that, overall, HRZE treatment caused a more substantial change
201 (in terms of the number of genes affected) in expression profile than NTZ when comparing pretreatment to 2
202 week treatment transcriptome samples, as measured by random forest/support vector machine ROC curves or
203 principal component analysis (Supplementary Figure S3A-B).


204
205 To identify specific RNA transcripts affected by each treatment, we used DESeq analysis on the paired-sample
206 transcript abundance of RNA and compared pretreatment samples to samples obtained at day 14 after HRZE
207 (n=8) or NTZ treatment (n=14) independently. The paired nature of samples was considered in the analysis to
208 account for person-specific baseline normalization. We found that 2 weeks of HRZE treatment was associated
209 with changes in 1374 transcripts at a p-value cutoff of $p < 0.05$ and 503 at a p-value cutoff of $p < 0.001$ (throughout,
210 all p-values from DESeq are adjusted using the Benjamini-Hochberg method for multiple comparisons).
211 Repeating the same analysis for NTZ-treated individuals, we identified 811 differentially expressed genes at a p-
212 value cutoff of $p < 0.05$ and only 15 at $p < 0.001$.

213
214 We determined the functional pattern of treatment-induced changes in overall transcript abundance, by
215 performing gene set enrichment analysis (GSEA)²⁶ (See Methods) using the ranked DESeq gene expression data
216 for the differentially expressed genes in each arm separately. In the HRZE arm we observed reduced expression
217 of the pathways of inflammatory response, IFN γ response, IFN α response, TNF α signaling via NF κ B, and IL6 JAK
218 STAT3, all of which are consistent with the immunologic effects of antibiotic induced reduction in the levels of
219 the bacterial pathogen, given the demonstrated relevance of these signaling pathways to pathogenesis^{12,15,27}
220 (Figure 3A). In contrast, NTZ treatment, which perturbed the microbiome without significantly affecting *Mtb*
221 bacterial load in the sputum, had the opposite effect. Inflammatory signaling pathways reduced by HRZE,
222 including TNF α signaling, IFN γ signaling, and type 1 interferon signaling, were all enriched by NTZ treatment
223 (Figure 3A). Several other pathways such as hypoxia, apoptosis, and reactive oxygen species (ROS), which are
224 considered hallmarks of immune dysregulation²⁸, were also enriched by NTZ treatment (Figure 3B). When
225 comparing the list of transcripts significantly affected by either HRZE (1374) or NTZ (811), after taking into
226 account person-specific gene normalization, we found that only 86 genes were affected by both treatments (p
227 < 0.05). Eighty of these genes had the same pre/post treatment pattern in HRZE and NTZ-treated individuals,

228 thus leaving 1294 (94.2%) and 731 (90.1%) to be HRZE and NTZ-specific changes to peripheral gene expression
229 (Figure 3C). Of the 86 genes affected by both HRZE and NTZ, only 10 were reported to be peripheral blood
230 transcriptomic markers of active tuberculosis^{12,13,15}. Interestingly, six active-TB associated genes belong to the
231 group of 80 genes that similarly respond to HRZE and NTZ (7.5%). The remaining four TB-related genes (P2RY14,
232 ADM, CARD16, DHRS9) belong to the group of six genes (P2RY14, NRN1, ADM, JAG1, CARD16, DHRS9) that were
233 reduced in expression and renormalized with HRZE but increased and exacerbated TB signature with NTZ (67%)
234 (Figure 3C).

235
236 To focus our analysis on validated transcriptomic markers of active TB from prior studies, we examined the
237 recently reported list of 373 transcripts that have been associated and validated in multiple human cohorts on
238 multiple sequencing platforms (microarray and RNAseq) to be differentially abundant between active and
239 healthy control and/or active and LTBI individuals¹⁷ in a comprehensive meta-analysis. In our study, we detected
240 361 of these 373 transcripts in pretreatment active TB subjects. We defined three classes of changes to these
241 transcripts with two weeks of HRZE or NTZ treatment: 1) *renormalization* (transcripts whose pre-post HRZE/NTZ
242 foldchange in expression displays the same sign (or direction) of the previously-reported fold-change between
243 active TB and control/LTBI; 2) *unchanged* (transcripts with no change in expression between pre-post HRZE/NTZ
244 administration); and 3) *exacerbation* (genes whose pre-post HRZE/NTZ fold-change sign is opposite to the
245 previously-reported fold-change between active TB and control/LTBI). Of the 361 transcripts, 173 (48%) were
246 found to be affected by HRZE. Of these 173, 151 (87%) renormalize with HRZE treatment, whereas 22 (13%)
247 exacerbate (Supplementary Table S1, Figure 4). In contrast, NTZ was found not only to have a smaller overall
248 effect on the active TB signature, but also to only contribute to exacerbation. Specifically, only 28 genes were
249 affected by NTZ (8%), of which 26 (96%) were in the exacerbation category (Supplementary Table S1, Figure 4).

250
251 Taken together, our data suggest that both HRZE and NTZ lead to changes in the peripheral transcriptomic
252 pattern of active TB, with HRZE having a more dramatic effect, at least as measured by the number of genes
253 differentially expressed before and after two weeks of therapy compared to NTZ, both overall as well as when
254 considering a previously-reported signature of active TB. Additionally, our analysis suggests that two weeks of
255 HRZE treatment normalizes almost 50% of the peripheral gene expression profile characteristic of active
256 tuberculosis, consistent with prior studies, whereas NTZ had the opposite effect: exacerbating the
257 transcriptional pattern for a subset of transcripts that reflect disease activity.



259

260 **Figure 3: Hallmark pathway gene set enrichment analysis and gene expression comparison in HRZE and NTZ**
 261 **treated cohorts. A,B.** Hallmark gene pathway changes associated with 2 weeks of HRZE (A) or NTZ (B). Positive
 262 are pathways overrepresented at 2 weeks of therapy, and negative are pathways underrepresented at 2 weeks,
 263 both compared to pretreatment. All pathways are significant ($p < 0.05$) with the associated Normalized
 264 Enrichment Score (NES) shown on the x axis, which considers pathway size. **C.** Overlap in genes that are
 265 differentially altered in both HRZE and NTZ treatments compared to pretreatment. Transcripts annotated in the
 266 left column in red (Up) rise with HRZE and NTZ. Transcripts annotated in blue (Down) are suppressed by both
 267 HRZE and NTZ. Genes annotated in green are down in HRZE and up in NTZ. The second column of vertical
 268 metadata scores each gene as either present or absent in prior active TB transcriptional signatures.

Relationships between gene expression and changes in the microbiome in the longitudinal treatment cohort

Resolution of disease manifestations by antibiotic therapy of a chronic, pro-inflammatory infection such as tuberculosis is likely to reflect a complex interplay of pathogen killing and resolution of inflammatory responses, which may occur with different temporal profiles²⁹. Although a primary effect of antibiotics is killing of the pathogen, perturbation of the microbiome during therapy might also affect disease resolution due to an independent effect on peripheral inflammation, but these two effects are difficult to uncouple and therefore remain hypothetical. Because we observed changes in peripheral transcriptomic profiles by both HRZE and NTZ in active TB subjects, in some cases divergent between HRZE and NTZ, despite the fact that NTZ did not significantly reduce *Mtb* bacterial load in the sputum, this dataset provided a unique opportunity to investigate potential effects of antibiotic induced microbiome changes on disease driven inflammation. We hypothesized that TB therapy-induced perturbations of the gut microbiota that might be predictive of the observed changes in host gene expression.

To decouple the effect of microbiome perturbation from *Mtb*-killing in peripheral inflammatory transcriptomics, we used a machine learning approach. Specifically, we built random forest regression (RFR) models³⁰ to predict the DESeq-normalized pre- and post-treatment expression profiles of each significantly differentially abundant transcript as a function of both *Mtb* bacterial load (TTP) (at day 0 and day 14) and of DESeq-normalized abundance of ASVs (microbiome components) (also at day 0 and day 14) found to be affected by each TB treatment, separately. We modeled data from each cohort independently because the treatment effects at the single gene and ASV level were distinct between each cohort and because at baseline there is no significant difference in microbiome and gene expression due to arm membership (PERMANOVA $p > 0.05$). We used the Boruta algorithm³¹ for feature selection in predicting the expression profile of each gene (see Methods). We reasoned that this approach was appropriately suited for this type of “large p, small n” multi-omics dataset common in clinical research³². Several advantages of RFR modeling include: being agnostic to model structure (e.g. non-parametric regression), not having to meet common assumptions underlying classical regression techniques, and being able to intrinsically perform ranked feature selection. Importantly, while the interpretation of RFR is apparently less immediate compared to traditional regression (e.g. there are per-se no regression coefficients or betas), downstream analysis, which includes Permuted Importance³³ and accumulated local effects calculations³⁴ (see Methods) allows for the estimation of the significance of predictors (e.g. TTP, microbiome constituents, etc.) as well as their effects on the dependent variable (e.g. host transcriptomic markers).

301 For both sets of HRZE- and NTZ-affected transcripts, we estimated the frequency of each feature to be identified
302 as important by the RFR model. We performed this analysis considering all differentially expressed genes in both
303 datasets (Supplementary Figure S4) as well as focusing only the 361 genes belonging to the list of 373 transcripts
304 previously reported as an active TB signature. Remarkably, this analysis identified bacterial load and the
305 abundance of members of Clostridia as the most important predictors of gene expression (Supplementary Figure
306 S6A and 5B). For the HRZE arm (Supplementary Figure S6A), change in bacterial load (TTP) was the top predictor
307 of the change in transcript abundance with treatment, which is found to be important in predicting the change
308 in 75% of the 173 active TB transcripts and HRZE affected transcripts (Supplementary Figure S6). This is
309 consistent with the idea that HRZE normalizes the active TB signature by reducing the pathogen burden in the
310 lung (Supplementary Figure S6C). Surprisingly, even though sputum bacterial load did not change in aggregate
311 in the NTZ cohort, TTP is still found to be the second most important feature in predicting changes in active TB
312 gene expression, as it is found to contribute to the abundance of 48% of the 27 active TB and NTZ affected
313 transcripts (Figure 3). We confirmed that the relationship between bacterial load and transcript abundance in
314 the NTZ cohort (obtained via RFR) was a biological signal by performing linear-mixed effect modeling (lme in R)
315 to predict the expression of each of these NTZ associated transcripts as a function of TTP and using patient ID
316 as a random effect (Supplementary Figure S4) (model: $\text{lme}(\sim \text{TTP}, \text{random} = \sim 1 | \text{Patient.ID})$). We found that
317 despite the lack of clinical efficacy of the NTZ drug as measured by average TTP in the treated group, transcripts
318 that are known to respond to TB bacterial load are altered in a direction that correlates with the TTP signal. This
319 reflects the fact that while the magnitude of TTP change was not clinically significant across the entire NTZ
320 cohort, person-specific changes in TTP were present in the NTZ cohort for TB-associated transcripts.

321
322 With respect to microbiome effects, Clostridia are predicted by both models to be the most important
323 microbiome component predicting the change in the inflammatory transcriptomic pattern that reflects active
324 TB and normalizes with treatment. Specifically, in the HRZE arm (Supplementary Figure S6A) *E. hallii* (ASV 336)
325 and *S. termitidis* (ASV 71) are the second and third-best predictors of the abundance of over 50% of the HRZE-
326 affected transcripts associated with active TB. In the NTZ arm (Supplementary Figure S6B) *G. formicilis* (ASV 27)
327 is identified as the most important predictor with over 50% of NTZ-affected active TB transcripts predicted to
328 co-vary with it. Of the other important microbiome features selected by the models, we observed the presence
329 of a number of well characterized short chain fatty acid-producing Clostridia (including *F. prausnitzii*, *Clostridium*
330 *spp.*, *B. lутii* in the HRZE group, or *D. longicatena* and *B. lутii* in the NTZ group), which are all depleted by the
331 anti-TB treatment (Supplementary Figure S6C-D). Interestingly both models identified the same ASV, *Clostridium*
332 XIVa *F. saccharivorans* (ASV 57) to be an important predictor of transcriptomic markers that are depressed by

333 both treatments. Peculiar to the NTZ-data based model is the identification as important variables of *S.*
334 *alactolyticus* (ASV 40), *E. faecium* (ASV 222) and *K. pneumoniae* (ASV 59) which are observed to significantly
335 increased in abundance and dominate several of the NTZ-treated individuals (Figure 2).


336
337 Variable importance estimation techniques such as Boruta allow determination of the presence of significant
338 associations among variables, but not their directionality (positive/negative effect). Therefore, we determined
339 the direction of the contribution of each important feature to the abundance of each of the modeled active TB
340 signature transcripts from the RFR modeling, by adapting the concept of accumulated local effects (ALE)
341 calculations (see Methods)³⁴ and using the sign of the average of the first-order derivative of the ALE plot as a
342 binary indicator for direction. As most of these plots are monotonic and continuous curves, the first order
343 derivative is a good approximation of the quantitative contribution of a hypothesized biologically relevant
344 predictor to transcript abundance, in this case microbiota constituents or change in *Mtb* bacterial load (TTP).
345 We displayed the sign of the *features x genes* matrices containing the first order derivative values (or slopes) as
346 clustered heatmaps (Figure 5A-B). For both the HRZE and NTZ dataset-derived models, we observed that sputum
347 bacterial load (TTP) clustered independently of the model-selected microbiome features (Figure 5A-B). The
348 effect of reducing sputum bacterial load was predominantly to normalize gene expression in the relevant
349 inflammatory pathways such as IFN γ and IFN α (negative contribution in heatmap for TTP means that rising TTP
350 (i.e., lower bacterial load) is associated with normalizing transcripts) (Figure 5A).

351
352 In the model trained on the NTZ treatment data, we find two opposing effects of NTZ induced microbiome
353 perturbation. Depletion of Clostridia by NTZ is predicted to contribute to the exacerbation of inflammatory
354 pathways of active TB observed in the transcriptomic data (Figure 5B: negative contribution in heat map=lower
355 Clostridia>>higher inflammatory transcripts) consistent with the anti-inflammatory properties of these
356 microbiota members. In contrast, the model predicts that pathobionts, whose abundance is enhanced by NTZ
357 (*E. faecium*, *K. pneumoniae* and *S. alactolyticus*, Figure 2C), have the opposite effect and exacerbate
358 inflammatory transcripts (Figure 5B: positive contribution in heat map=higher pathobionts>>higher
359 inflammatory transcripts). Pathobionts are potentially pathogenic symbionts of the microbiota, and include *E.*
360 *coli*, *K. pneumoniae* and *S. alactolyticus*.

361
362 Taken together, our data and related computational analyses show that the changes in inflammatory gene
363 expression that accompany treatment of TB may be mediated both by the anti-microbial activity of the drugs
364 that lead to pathogen clearance and by antibiotic induced changes in microbiome composition. Our model

365 identifies two modules of microbiome-inflammatory effects. The first is the exacerbation of TB associated
366 inflammation by depletion of Clostridia, which is evident in both the HRZE and NTZ models. Additionally, the
367 enhancement of pathobionts such as Klebsilla, which only occurs with NTZ, also exacerbates inflammatory
368 pathways. Based on this modelling, we predict that successful disease resolution will be associated with
369 preservation of Clostridia, whereas their depletion and consequent enhancement of Proteobacteria and Bacilli
370 pathobionts might slow resolution or even support inflammatory exacerbation.


371



372

373 **Figure 4: Effect of HRZE and NTZ on active TB transcriptional signatures.** **A.** Summary of the number of active
374 TB genes that renormalize (blue), do not change (grey), or exacerbate (red) as a result of each drug
375 administration. **B.** Comparison of log₂ Fold Change in gene expression from¹⁷ where the 373 active TB signature
376 was first introduced with the log₂ Fold Change of the same genes pre-post HRZE (left) or NTZ (right) from this
377 study. A significant positive correlation (Pearson's $p < 0.01$) is observed for the 151 genes that renormalize with
378 HRZE treatment.

379



380
381 **Figure 5: Hallmark Pathway Analysis of peripheral gene transcriptional data and its relationship to**
382 **gastrointestinal microbiota and *M. tuberculosis* bacterial load (TTP).** We used Random Forest regression to
383 model the change in gene expression as a function of gastrointestinal microbiota and reduction in bacterial load
384 (TTP). Top predictors are shown for both HRZE (**A**) and NTZ (**B**) study arms. The contribution of each predictor
385 to a gene's expression profile is estimated by calculating the derivative (or slope) of the accumulated local
386 effects (ALE) plots between each predictor and each modeled gene (see Methods). The sign of the derivative is
387 displayed in the heatmaps. On the right, the presence or absence of a particular gene in a Hallmark gene set is

indicated. If that gene is in the pathway, it is marked as red. Some genes are in multiple pathways, and only the significantly enriched pathways from the differential analysis (of the full transcriptome) are shown. The Normalized Enrichment Score (NES) is how significantly overrepresented a particular pathway is in the treated case (comparing pretreatment vs treatment in both instances) and takes into account pathway size. A majority of the organisms are obligate anaerobic Clostridia, from the following clusters: *Clostridium disporicum* (Cluster I), *Faecalibacterium prausnitzii* (Cluster IV), *Eubacterium hallii* (Cluster XIVa), *Sporobacter termitidis* (Cluster XI), *Fusicatenibacter saccharivorans* (Cluster XIVa), *Clostridium fimetarium* (obligate anaerobe), *Clostridium innocuum* (obligate anaerobe), *Gemmiger formicilis* (obligate anaerobe), *Blautia luti* (Cluster XIVa), *Dorea longicatena* (obligate anaerobe), *Hungatella hathewayi* (obligate anaerobe).

Relationship of the microbiome and peripheral gene expression in a healthy control validation cohort

The results from our primary analysis in the longitudinal treatment cohort demonstrate that specific gastrointestinal bacteria are associated with proinflammatory peripheral blood gene signatures in humans. Specifically, we predict that higher abundance of Clostridia is negatively associated with inflammation (e.g. $INF\alpha$, $INF\gamma$, IL6/JAK/STAT3, Inflammatory Response gene signatures) while high abundance of commonly known pathobionts including *E. coli*, *Klebsiella*, *Citrobacter*, *Streptococcus* and *Enterococcus* promotes exacerbation of these signatures. To determine the generality of these results we analyzed a control set of human data from two healthy cohorts. A subset of these data were previously reported in our work⁵, and come from a cross-sectional study of healthy household contacts of active pulmonary TB patients (termed Family Contacts, FC) and healthy unexposed donors from the same community in Haiti (termed Community Controls, CC) (see Methods). For these two new cohorts we have a total of 52 healthy control individuals (18 FC and 36 CC) for which we gathered both microbiome 16S rRNA sequencing data as well as peripheral blood transcriptomics for the same individuals.

We analyzed the blood transcriptomics and performed correspondence analysis on the DSEeq2 normalized abundance of the transcripts in each sample (Figure 6A). We observed pretreatment and treated HRZE and NTZ sample clustering away from FC and CC samples, highlighting the fact that individuals with active TB, even while on treatment, represent the transcriptional profile of active TB patients has not returned to a profile of healthy controls (Supplementary Figure S7). More importantly we see that FC and CC samples do not separate in this ordination, suggesting that both cohorts can be used as healthy controls in the subsequent analysis.

To link transcript abundance to immune pathway enrichment we utilized gene set variation analysis (GSVA) (see Methods)³⁵. GSVA enables computing an enrichment score for any defined list of genes (taken as a surrogate

420 for a biological pathway) in each sample. For each sample, each pathway generates a normalized enrichment
421 score (NES) that can be used for downstream analysis to compare pathway profiling across samples.
422 Importantly, this method is completely agnostic to the phenotype label of the sample.

423
424 We performed unsupervised clustering on the samples-by-pathway NES scores, and found that individuals from
425 FC and CC cluster separately from individuals in the longitudinal treatment cohort (Figure 6B). We observed that
426 the NES score signature comparisons between the FC and CC individuals, and individuals before treatment and
427 after two-weeks of HRZE or NTZ have qualitatively reduced enrichment in $INF\alpha$, $INF\gamma$, IL6/JAK/STAT3, and
428 Inflammatory Response (Figure 6B). As discussed, these are the pathways that renormalize with HRZE treatment
429 and exacerbate with NTZ in the longitudinal dataset (Figure 3). These are also the pathways negatively
430 associated with Clostridia abundance and positively with Proteobacteria and Bacilli abundance in the random
431 forest modeling analysis (Figure 5). Interestingly, post HRZE treatment individuals have an enrichment
432 distribution for this pathway which is in between FC and CC individuals and NTZ/Pretreatment samples thus
433 reinforcing the result that HRZE treatment promotes renormalization (Figure 6C).

434
435 Even though FC and CC individuals show an overall lower inflammatory enrichment compared to active TB
436 samples, and samples post HRZE and NTZ treatment (Figure 6C), we hypothesize that the FC and CC intragroup
437 inflammatory pathway enrichment distributions would correlate with the abundance of microbes that we found
438 to predict the expression of genes associated with these pathways in the Random Forest Modeling analysis
439 performed on the HRZE and NTZ microbiome/transcriptomic data (Figure 5 and Figure S6). We performed
440 Pearson's correlation analysis between these NES values, and the abundance of ASVs from bacterial orders
441 having representative species found to be predictive of the abundance of these inflammatory pathways in the
442 longitudinal treatment cohorts (Figure 6D). In these two human cohorts, we again observe a negative
443 association between Clostridia ASVs and $INF\alpha$, $INF\gamma$, IL6/JAK/STAT3, and Inflammatory Response pathways, as
444 well as a positive association between these pathways and the abundance of pathobionts including
445 *Enterococcus*, *Streptococcus*, *E. coli* and *Klebsiella*. We interpret these correlations as independent validation of
446 the observation that specific microbiome members are strongly correlated with peripheral inflammatory
447 response pathways in both inflammatory disease states and in homeostatic conditions.

461 Discussion

462 Since the advent of high-throughput microbiome characterization, it has become clear that antibiotics are one
463 of the most common and severe perturbing influences on human microbiome composition, with both acute and
464 longer lasting effects^{36,37}. It also has become evident that the specific microbiome constituents have specific
465 effects on host immunity, including the abundance and function of immune cell subsets²¹. Significant prior data
466 have documented the effects of antibiotics on microbiome composition and function and the consequent
467 influence of these microbiome factors on specific immune cell populations³⁸, with the majority of these findings
468 derived using *in vivo* mouse models. While there is no doubt that microbiota dynamics affect host immunity⁶, it
469 remains unknown to what degree antibiotic induced perturbation of the microbiome may modify the outcome
470 of treatment of infection. It is conceivable that antibiotics work to clear infection both due to direct pathogen
471 killing and by immune modulation through the microbiome. It is also possible that the pathogen killing effect of
472 antibiotics may be partially counteracted by detrimental immune effects induced by microbiome perturbation.
473 Such dynamics may be particularly relevant to the treatment of chronic infections such as tuberculosis, in which
474 antibiotic therapy is prolonged and the disease manifestations reflect a mixture of pathogen burden and the
475 balance of inflammatory mediators that cause tissue destruction and chronic symptomatology^{29,39}.

476
477 Antibiotic sensitive tuberculosis is treated with six months of antibiotics with predominantly mycobacterial
478 specific agents. In this study we report the early microbiome effects of HRZE therapy in subjects with active TB
479 and demonstrate that the same changes observed in a human cross-sectional study of TB treatment¹⁹
480 (comparing vs cured and LTBI individuals) were present after just two weeks of treatment. As previously
481 shown¹⁹, we conclude that HRZE treatment has a rapid and narrow effect on the intestinal Class of Clostridia, a
482 finding that was also demonstrated in mice^{18,40}. We note that given the mycobacterial-specific nature of TB
483 drugs, and the combinatorial nature in which small molecules interact to affect the microbiome, it was difficult
484 to predict that primarily Clostridia, in the Phylum Firmicutes, would be targeted by HRZE therapy, whereas
485 Actinobacteria, the phylum to which *Mtb* belongs, are relatively unaffected. Experiments in mice have
486 demonstrated that this anti-Clostridia effect is primarily driven by rifampicin¹⁸. Clostridia are immunologically
487 active components of the microbiota through their production of metabolites such as short chain fatty acids
488 and other compounds^{2,5,6,41,42}.

489
490 In this work, in addition to determining the microbiome perturbing effect of TB treatment at 2 weeks of therapy,
491 we also leveraged a dataset derived from a clinical trial comparing two TB treatment regimens in a 2-week early
492 bactericidal activity (EBA) format⁴³. This comparison allowed us to dissect the relative contributions of pathogen

493 killing and microbiome perturbation to disease resolution because one treatment arm, standard therapy, both
494 reduced *Mtb* bacterial burden and perturbed the microbiome, whereas NTZ had no effect on average *Mtb*
495 burden, but did perturb the microbiome in a fashion that overlapped with HRZE. Additionally, the availability of
496 systemic inflammatory markers derived from peripheral blood transcriptomics allowed us to determine the
497 relative contribution of pathogen sterilization and microbiome disruption in predicting the resolution of
498 inflammatory markers of disease. We find that even though NTZ did not reduce the burden of *Mtb* in the
499 sputum, this molecule nevertheless: 1. caused perturbations responsible for obliterating a large number of
500 obligate anaerobes (e.g. Clostridia), 2. facilitated domination by a number of pathobionts, and 3. affected
501 peripheral gene expression of TB-related and TB-unrelated genes. Specifically, two independently-built
502 computational models (one calibrated on HRZE-treated individuals, the other on NTZ) to link gene expression
503 with microbiota and *Mtb* bacterial load changes showed that changes in active TB transcript patterns were not
504 only correlated with the ability of the drug to reduce *Mtb* bacterial burden, but also with the abundance of
505 Clostridia and pathobionts selected by NTZ. Specifically, the model proposed that reduced *Mtb* load in the
506 sputum and increased abundance of Clostridia are predictive of normalization of the inflammatory transcript
507 profile of active TB. In contrast, increased abundance of pathobionts, including *E. faecium* and *K. pneumoniae*,
508 was predictive of inflammatory exacerbation in the NTZ cohort.

509
510 To validate the inferred microbiome-host inflammatory relationship, we mined microbiome and blood
511 transcriptomic profiling from an independent human cohort of healthy Haitian individuals. Remarkably, despite
512 the reduced peripheral levels of inflammatory pathways compared subjects with active TB, we observe that
513 members of the Class Clostridia negatively correlate with pro inflammatory pathways and the reverse for the
514 intestinal pathobionts. This validation data strongly supports our conclusion that microbiome composition sets
515 the tone of systemic inflammation, both in disease states and in homeostatic conditions. Further, it is consistent
516 with the prior findings in both humans and animals that Clostridia have been associated with induction of anti-
517 inflammatory or benign conditions, whereas enrichment in *Enterobacteriaceae* members has been found to be
518 immune-modulating and to alter immune cells populations in the periphery⁴⁴.

519
520 This opposing predictive effects of immune modulating Clostridia and *Mtb* bacterial load (TTP) inferred by the
521 RFR model in HRZE vs. NTZ-treated individuals may be interpreted as follows: when a treatment like HRZE is
522 effectively killing *Mtb*, the rapid reduction in pathogen load in the lung dominates the normalization markers of
523 inflammation, but there are also opposing effects on normalization originating from HRZE-induced microbiome
524 perturbation. In the NTZ group, Clostridia are eradicated, and Proteobacteria and Bacilli are enriched, but

without pathogen killing, the microbiota effects are dominant. This NTZ group allows us to deduce opposing effects of Clostridia and pathobionts, with preservation of the former favoring inflammatory resolution and the latter favoring inflammatory exacerbation. This is consistent with our findings that after two weeks of NTZ treatment there is an exacerbation of TB associated inflammatory pathways (Figure 3B).

Finally, given the challenge of explaining the relationship between microbiome composition and peripheral gene expression with paired samples, randomized to drug combinations with vastly different effects on both body systems, we strove to use an appropriate mathematical approach for this type of analysis: random forest regression. While there are a variety of statistical and machine learning techniques able to investigate relationships between complex multiparametric datasets (“large p ”: microbiome composition, RNAseq data, clinical metadata, randomization cohort, paired-sample baseline normalization, etc.), and a “small n ” of individuals in early phase clinical trials, Random Forests are adequate for microbiome purposes, as they have been shown to outperform Support Vector Machines in some instances, especially for continuous variable data, and need initialization of a smaller set of parameters compared to other deep-learning methods. We believe that our results highlight the utility of these models to: 1. Provide evidence for or against a particular hypothesis about clinically significant relationships between many potentially related parameters, and 2. To provide hypothesis generating relationships between the multi-omic constituents (i.e., features) of these models, which can be further tested in mice, validation cohorts, or other model systems.

Our data indicates that within the first 14 days of treatment of tuberculosis, resolution of the active inflammatory response of TB (as measured by peripheral blood transcriptomics) may be strongly affected both by reducing *Mtb* burden as well as through antimicrobial-induced microbiome perturbations that may act directly on systemic immune function. Among the pathways tightly correlated with both factors are the signature activated pathways of active TB disease: IFN γ , type I interferon, and TNF α ¹². There is growing evidence that the outcome of active TB reflects a mixture of pathogen burden and cytokine networks that include IL-1 and IFN α , with the latter acting to exacerbate disease³⁹. Our findings indicate that the microbiome perturbation that accompanies TB treatment is a predictor of the normalization of these same pathways during early treatment, suggesting that microbiome perturbation could modify or predict the rapidity of disease resolution. In the first two weeks of treatment, pathogen killing is the dominant factor, but microbiome dependent modulation of inflammatory responses during treatment may assume an important role during the later phases of treatment when pathogen killing slows. The validation of the relationships between microbiome composition and peripheral gene expression in a healthy control cohort, especially for the collective expression

557 of these same pro- and anti-inflammatory pathways, suggests that these relationships may extend into other
558 populations. Whether these relationships are causal, or biomarkers of another state will remain at the forefront
559 of future study design. Future work will be directed to applying the analytical tools and study design presented
560 here to later time points in the TB treatment course to examine whether microbiome perturbation during
561 treatment associates with clinically relevant treatment outcomes, and whether the abundance of Clostridia
562 correlates with rapidity of *Mtb* sterilization or the resolution of the inflammatory response that accompanies
563 active TB. Such data might help support trials to test microbiome monitoring as a predictor of TB treatment
564 outcome or help understand interindividual heterogeneity in treatment outcomes.

565

566 **Materials and Methods**

567 **Ethical statement and study approval**

568 All volunteers provided written informed consent to participate in this study. All human studies were reviewed
569 and approved by the IRBs of both Weill Cornell Medicine and Groupe Haitien d'étude du Sarcome de Kaposi et
570 des Infections Opportunistes (GHESKIO) Centers (Port-au-Prince, Haiti). Participants provided informed consent
571 prior to peripheral blood draw for whole blood collection and stool collection for 16S rDNA sequencing. All
572 methods and procedures were performed in accordance with the relevant institutional guidelines and
573 regulations.

575 **Donor recruitment and protection of human subjects**

576 **Longitudinal treatment cohort:** Donors were enrolled through the Clinical Trials Unit at GHESKIO. Pulmonary
577 TB was diagnosed by clinical symptoms, chest radiograph consistent with pulmonary TB, and positive molecular
578 testing. All participant samples were deidentified on site using a barcode system before they were shipped to
579 Weill Cornell Medicine (WCM)/Memorial Sloan Kettering Cancer Center (MSKCC) for analysis. All clinical
580 metadata was collected on site and managed through the REDCap data management system.⁴⁵

581
582 **Human healthy control arm:** We recruited families of active pulmonary TB patients where at least 2 siblings
583 within the family were diagnosed with active TB. These criteria were designed to select for households with high
584 risk of transmission of Mtb. Household contacts were then recruited if they had been sleeping in the same house
585 with a TB case for at least 1 month during the 6 months prior to the TB case diagnosis. Contacts underwent
586 clinical screening for active TB symptoms and IGRA testing. Healthy donors without history of TB contacts or
587 disease were recruited from the same community as a control group for exposure and also underwent clinical
588 screening for active TB symptoms and IGRA testing. All donors provided informed consent prior to peripheral
589 blood donation for whole blood collection for RNAseq and stool submission for DNA extraction and 16S rDNA
590 sequencing.

592 **Microbial DNA extraction from stool**

593 DNA extraction from stool was performed as described.¹⁹ Stool specimens were collected and stored for less
594 than 24 hours at 4°C, aliquoted (~2 ml each), frozen at -80°C, and shipped to WCM/MSKCC. About 200 – 500
595 mg of stool from frozen samples was suspended in 500 µl of extraction buffer (200 mM Tris-HCl [Thermo Fisher
596 Scientific], pH 8.0; 200 mM NaCl [Thermo Fisher Scientific]; 20 mM EDTA [MilliporeSigma]), 210 µl of 20% SDS,
597 500 µl of phenol/chloroform/isoamyl alcohol (25:24:1; MilliporeSigma), and 500 µl of 0.1-mm-diameter

598 zirconia/silica beads (Biospec Products). Samples were lysed via mechanical disruption with a bead beater
599 (Biospec Products for 2 minutes, followed by 2 extractions with phenol/chloroform/isoamyl alcohol [25:24:1]).
600 DNA was precipitated with ethanol and sodium acetate at -80°C for at least 1 hour, resuspended in 200 μl of
601 nuclease-free water, and further purified with QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's
602 protocols. DNA was eluted in 200 μl of nuclease-free water and stored at -20°C .

604 **16S rDNA sequencing**

605 Primers used to amplify rDNA were: 563F (59-nnnnnnnn-NNNNNNNNNNNN-AYTGGGYDTAAAGN G-39) and
606 926R (59-nnnnnnnn-NNNNNNNNNNNN-CCGTCAATTYHTTTR AGT-39). Each reaction contained 50 ng of purified
607 DNA, 0.2 mM dNTPs, 1.5 μM MgCl_2 , 1.25 U Platinum TaqDNA polymerase, 2.5 μl of 10 \times PCR buffer, and 0.2 μM
608 of each primer. A unique 12-base Golay barcode (Ns) preceded the primers for sample identification after
609 pooling amplicons. One to 8 additional nucleotides were added before the barcode to offset the sequencing of
610 the primers. Cycling conditions were the following: 94°C for 3 minutes, followed by 27 cycles of 94°C for 50
611 seconds, 51°C for 30 seconds, and 72°C for 1 minute, where the final elongation step was performed at 72°C for
612 5 minutes. Replicate PCRs were combined and were subsequently purified using the Qiaquick PCR Purification
613 Kit (Qiagen) and Qiagen MinElute PCR Purification Kit. PCR products were quantified and pooled at equimolar
614 amounts before Illumina barcodes and adaptors were ligated on using the Illumina TruSeq Sample Preparation
615 procedure. The completed library was sequenced on an Illumina Miseq platform per the Illumina recommended
616 protocol.

618 **16S rDNA bioinformatics analysis**

619 Forward and reverse 16S MiSeq-generated amplicon sequencing reads were dereplicated and sequences were
620 inferred using dada2.⁴⁶ Potentially chimeric sequences were removed using consensus-based methods.
621 Taxonomic assignments were made using BLASTN against the NCBI refseq rna database. These files were
622 imported into R and merged with a metadata file into a single Phyloseq object.

623
624 Deposition of data. 16S rDNA sequencing data is deposited with the SRA under accession no. PRJNA445968
625 (<https://www.ncbi.nlm.nih.gov/bioproject/PRJNA445968>). Code used for 16S analysis is available at
626 <https://wipperman.github.io/TBRU/>.

630 Computational Analysis

631 Raw ASV count data was normalized using DESeq2⁴⁷. DESeq2 was used to make differential abundance and
632 expression comparisons between treatment cohorts and between individual pre and post-treatment samples
633 for both microbiota and host gene count data.

634
635 To determine how the anti-TB treatment affects both microbiome and peripheral gene expression profiles we
636 performed differential analysis on the counts data obtained by microbiome DNA and peripheral blood RNA
637 sequencing. As the primary endpoint of the clinical trial was powered to determine differences in *Mtb* load
638 (TTP), we had to determine the statistical power available to identify significant differences in the abundance of
639 both microbiota members and in the expression of peripheral genes. We ran power calculations (see Methods)
640 to determine that with 16 microbiome samples and 8 RNAseq samples for the HRZE cohort, with 80% power at
641 $\alpha < 0.05$, we could detect a fold change of 1.4 for microbiome difference and a fold change of 1.8 for mRNA
642 transcripts. In the NTZ cohort, with 18 microbiome samples and 14 RNAseq samples, with 80% power at $\alpha < 0.05$,
643 we can detect a fold change of 1.4 for microbiome differences and a fold change of 1.6 for mRNA transcripts.
644 Additionally, we utilized DESeq in our analyses using baseline normalization within an individual as the gold
645 standard. Power calculations were performed with the RNAseqPower package in R. For microbiome data we
646 calculated a biological coefficient of variation of 0.3, and for RNAseq, we used a coefficient of variation of 0.4.
647 We estimated the expected minimum fold change that we could observe for each group based on the sample
648 size, sequencing depth, and an $\alpha < 0.05$.

649
650 To test whether there were differences between groups, we employed PERMANOVA using the Adonis function
651 in the Vegan R package (<https://cran.r-project.org/web/packages/vegan/vegan.pdf>), which partitions a distance
652 matrix of ASV count data and runs one-way ANOVA between groups of samples.

653
654 To predict the post-pre fold change in abundance of HRZE and NTZ-affected host genes as a function of the
655 corresponding fold change in abundance of microbiota ASVs and TTP using Random Forest Regression.³⁰ To
656 perform feature selection for each gene and rank features based on their prediction importance we used
657 Boruta⁴⁸. Boruta is a RF classification and regression wrapper for feature selection that allows identification of
658 variables important for the prediction task while also removing redundant ones. Boruta creates a copy of each
659 independent variable and shuffles them to remove correlation with the original variables (shadow variables).
660 Using this augmented set Boruta builds a RF model and performs a Variable Importance Estimation of all the
661 independent variables (both original and shadow). For every variable it then computes a normalized accuracy

662 score. A true variable is important if its normalized accuracy score is significantly greater than that of shadow
663 variables.

664
665 Accumulated Local Effect (ALE) plots were implemented to compute how the change in the expression of each
666 modeled host gene is affected by the level of each predictor identified as important by the forest model. Code
667 to analyze the data and to reproduce all the figures and results is available on Github at
668 <https://wipperman.github.io/TBRU/>.

670 **Within sample GSEA analysis**

671 The ssGSEA (single sample gene set enrichment analysis) method⁴⁹ was used to profile within-sample
672 differences between pathways from the MiSigDB Hallmark pathways list⁵⁰ with the GSVA package in R³⁵. The
673 MiSigDB Hallmark pathways list is a well validated set of general curated biological pathways that can give
674 insight into specific biological and cellular processes. Additionally, we obtained a list of well validated active TB
675 signatures from the TBSignatureProfiler R package (David Jenkins, Yue Zhao, W. Evan Johnson and Aubrey
676 Odom (2020). TBSignatureProfiler: Profile RNA-Seq Data Using TB Pathway Signatures. R package version
677 0.0.0.9005. <https://github.com/comphiomed/TBSignatureProfiler>. Variance stabilized transformed (vst) counts
678 derived from DESeq2 were used as input into the GSVA function in the GSVA R package with default parameters
679 and scaled Normalized Enrichment Scores (NES) were plotted as heatmaps. Importantly, unlike classical GSEA,
680 this analysis is agnostic to sample phenotype.

682 **Author Contributions**

683 Patient recruitment, enrollment, and sample collection were contributed by LM, KM, KFW, JB, and SCV;
684 Laboratory experiments were performed by MFW and CKV; Data analysis was performed by MFW, SB, VB; Wrote
685 manuscript: MFW, SB, MSG, VB; Edited manuscript: all authors.

686
687 MFW and SB are co-first authors, and MSG and VB are co-last authors. Co-authorship and author order were
688 determined by recognition that the integration of the nuances clinical trial data and mathematical modeling are
689 different skillsets found in different laboratory environments. Each were important components to the validity
690 and message of this manuscript.

694 **Conflicts of Interest**

695 MFW is currently an employee and shareholder of Regeneron Pharmaceuticals, Inc. MSG reports consulting fees
696 and equity in Vedanta Biosciences, Inc., and consulting fees from Takeda Pharmaceutical Co., Ltd. VB is
697 supported by a Sponsored Research Agreement from Vedanta Biosciences, Inc.

698

699 **Funding**

700 MFW, CKV, YT, KW, CN, DWF, MSG acknowledge funding from the Tri-I TBRU (grant: U19AI111143). CV
701 acknowledges support from K08AI132739. MFW acknowledges support from the National Center for Advancing
702 Translational Sciences (grant: TL1TR002386-02). Support for NCT02684240 came primarily from the Abby and
703 Howard P. Milstein Program in Chemical Biology and Translational Medicine. VB acknowledges support from
704 the National Science Foundation (grant: 1458347). This work was supported by P30 CA008748.

705

706 References

- 707 1. Martin, C.R., Osadchiy, V., Kalani, A. & Mayer, E.A. The Brain-Gut-Microbiome Axis. *Cell Mol*
708 *Gastroenterol Hepatol* **6**, 133-148 (2018).
- 709 2. Atarashi, K., *et al.* Treg induction by a rationally selected mixture of Clostridia strains from the human
710 microbiota. *Nature* **500**, 232-236 (2013).
- 711 3. Atarashi, K., *et al.* Induction of colonic regulatory T cells by indigenous Clostridium species. *Science* **331**,
712 337-341 (2011).
- 713 4. Tanoue, T., *et al.* A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. *Nature*
714 **565**, 600-605 (2019).
- 715 5. Vorkas, C.K., *et al.* Mucosal-associated invariant and gammadelta T cell subsets respond to initial
716 Mycobacterium tuberculosis infection. *JCI Insight* **3**(2018).
- 717 6. Campbell, C., *et al.* Extrathymically Generated Regulatory T Cells Establish a Niche for Intestinal Border-
718 Dwelling Bacteria and Affect Physiologic Metabolite Balance. *Immunity* **48**, 1245-1257 e1249 (2018).
- 719 7. Levan, S.R., *et al.* Elevated faecal 12,13-diHOME concentration in neonates at high risk for asthma is
720 produced by gut bacteria and impedes immune tolerance. *Nat Microbiol* (2019).
- 721 8. Grigg, J.B. & Sonnenberg, G.F. Host-Microbiota Interactions Shape Local and Systemic Inflammatory
722 Diseases. *J Immunol* **198**, 564-571 (2017).
- 723 9. Wang, Z., Arat, S., Magid-Slav, M. & Brown, J.R. Meta-analysis of human gene expression in response to
724 Mycobacterium tuberculosis infection reveals potential therapeutic targets. *BMC Syst Biol* **12**, 3 (2018).
- 725 10. Kaforou, M., *et al.* Detection of tuberculosis in HIV-infected and -uninfected African adults using whole
726 blood RNA expression signatures: a case-control study. *PLoS Med* **10**, e1001538 (2013).
- 727 11. Zak, D.E., *et al.* A blood RNA signature for tuberculosis disease risk: a prospective cohort study. *Lancet*
728 **387**, 2312-2322 (2016).
- 729 12. Berry, M.P., *et al.* An interferon-inducible neutrophil-driven blood transcriptional signature in human
730 tuberculosis. *Nature* **466**, 973-977 (2010).
- 731 13. Lesho, E., *et al.* Transcriptional responses of host peripheral blood cells to tuberculosis infection.
732 *Tuberculosis (Edinb)* **91**, 390-399 (2011).
- 733 14. Ottenhoff, T.H., *et al.* Genome-wide expression profiling identifies type 1 interferon response pathways
734 in active tuberculosis. *PLoS One* **7**, e45839 (2012).
- 735 15. Bloom, C.I., *et al.* Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary
736 sarcoidosis, pneumonias and lung cancers. *PLoS One* **8**, e70630 (2013).
- 737 16. Cliff, J.M., *et al.* Distinct phases of blood gene expression pattern through tuberculosis treatment
738 reflect modulation of the humoral immune response. *J Infect Dis* **207**, 18-29 (2013).
- 739 17. Singhania, A., *et al.* A modular transcriptional signature identifies phenotypic heterogeneity of human
740 tuberculosis infection. *Nat Commun* **9**, 2308 (2018).
- 741 18. Namasivayam, S., *et al.* Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by
742 conventional anti-tuberculosis therapy. *Microbiome* **5**, 71 (2017).
- 743 19. Wipperfman, M.F., *et al.* Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the
744 microbiome that persists long after therapy is completed. *Sci Rep* **7**, 10767 (2017).
- 745 20. Faith, J.J., Ahern, P.P., Ridaura, V.K., Cheng, J. & Gordon, J.I. Identifying gut microbe-host phenotype
746 relationships using combinatorial communities in gnotobiotic mice. *Sci Transl Med* **6**, 220ra211 (2014).
- 747 21. Geva-Zatorsky, N., *et al.* Mining the Human Gut Microbiota for Immunomodulatory Organisms. *Cell*
748 **168**, 928-943 e911 (2017).
- 749 22. Shigyo, K., *et al.* Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis.
750 *Antimicrob Agents Chemother* **57**, 2834-2837 (2013).
- 751 23. K. F. Walsh, K.M., M. H. Lee, S. C. Vilbrun, L Mathurin, D Jean Francois, M Zimmerman, F Kaya, N Zhang,
752 K Saito, O Ocheretina, R Savic, V Dartois, W. D. Johnson, J. W. Pape, C Nathan, D. W. Fitzgerald. Early


- 753 bactericidal activity trial of nitazoxanide for pulmonary tuberculosis. *Antimicrobial Agents and*
754 *Chemotherapy* (2020).
- 755 24. Harausz, E.P., *et al.* Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro
756 and in whole blood culture. *Tuberculosis (Edinb)* **98**, 92-96 (2016).
- 757 25. Taur, Y., *et al.* Intestinal domination and the risk of bacteremia in patients undergoing allogeneic
758 hematopoietic stem cell transplantation. *Clin Infect Dis* **55**, 905-914 (2012).
- 759 26. Subramanian, A., *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting
760 genome-wide expression profiles. *Proc Natl Acad Sci U S A* **102**, 15545-15550 (2005).
- 761 27. Glickman, M.S., Cox, J.S. & Jacobs, W.R., Jr. A novel mycolic acid cyclopropane synthetase is required
762 for cording, persistence, and virulence of Mycobacterium tuberculosis. *Mol Cell* **5**, 717-727 (2000).
- 763 28. Krzywinska, E. & Stockmann, C. Hypoxia, Metabolism and Immune Cell Function. *Biomedicines* **6**(2018).
- 764 29. Pirofski, L.-A. & Casadevall, A. Antimicrobial therapy in the context of the Damage-response
765 framework: The prospect of optimizing therapy by reducing host damage. *Antimicrobial agents and*
766 *chemotherapy*, AAC.01800-01819 (2019).
- 767 30. Haran, J.P., *et al.* Alzheimer's Disease Microbiome Is Associated with Dysregulation of the Anti-
768 Inflammatory P-Glycoprotein Pathway. *MBio* **10**(2019).
- 769 31. Miron B. Kursa, W.R.R. Feature Selection with the Boruta Package. *Journal of Statistical Software,*
770 *Articles* **36**, 1-13 (2010).
- 771 32. Johnstone, I.M. & Titterton, D.M. Statistical challenges of high-dimensional data. *Philos Trans A*
772 *Math Phys Eng Sci* **367**, 4237-4253 (2009).
- 773 33. Altmann, A., Tolosi, L., Sander, O. & Lengauer, T. Permutation importance: a corrected feature
774 importance measure. *Bioinformatics* **26**, 1340-1347 (2010).
- 775 34. Apley, D.W. & Zhu, J. Visualizing the Effects of Predictor Variables in Black Box Supervised Learning
776 Models. in *arXiv e-prints* (2016).
- 777 35. Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq
778 data. *BMC Bioinformatics* **14**, 7 (2013).
- 779 36. Dethlefsen, L. & Relman, D.A. Incomplete recovery and individualized responses of the human distal
780 gut microbiota to repeated antibiotic perturbation. *Proc Natl Acad Sci U S A* **108 Suppl 1**, 4554-4561
781 (2011).
- 782 37. Lavelle, A., *et al.* Baseline microbiota composition modulates antibiotic-mediated effects on the gut
783 microbiota and host. *Microbiome* **7**, 111 (2019).
- 784 38. Morgun, A., *et al.* Uncovering effects of antibiotics on the host and microbiota using transkingdom
785 gene networks. *Gut* **64**, 1732-1743 (2015).
- 786 39. Mayer-Barber, K.D., *et al.* Host-directed therapy of tuberculosis based on interleukin-1 and type I
787 interferon crosstalk. *Nature* **511**, 99-103 (2014).
- 788 40. Namasivayam, S., Sher, A., Glickman, M.S. & Wipperfurth, M.F. The Microbiome and Tuberculosis: Early
789 Evidence for Cross Talk. *MBio* **9**(2018).
- 790 41. Arpaia, N., *et al.* Metabolites produced by commensal bacteria promote peripheral regulatory T-cell
791 generation. *Nature* **504**, 451-455 (2013).
- 792 42. Gold, M.C., *et al.* Human mucosal associated invariant T cells detect bacterially infected cells. *PLoS Biol*
793 **8**, e1000407 (2010).
- 794 43. KF Walsh MD MPH, K.M.P., MH Lee PhD, SC Vilbrun MD, L Mathurin MD, D Jean, Francois, M.Z.P., F
795 Kaya PhD, N Zhang PhD, K Saito MD, O Ocheretina PhD,, R Savic PhD, V.D.P., WD Johnson MD, JW Pape
796 MD, C Nathan MD, DW Fitzgerald & MD. Early bactericidal activity trial of nitazoxanide for pulmonary
797 tuberculosis. (2019).
- 798 44. Matheoud, D., *et al.* Intestinal infection triggers Parkinson's disease-like symptoms in Pink1(-/-) mice.
799 *Nature* (2019).

- 800 45. Harris, P.A., *et al.* Research electronic data capture (REDCap)--a metadata-driven methodology and
801 workflow process for providing translational research informatics support. *J Biomed Inform* **42**, 377-
802 381 (2009).
- 803 46. Callahan, B.J., *et al.* DADA2: High-resolution sample inference from Illumina amplicon data. *Nat*
804 *Methods* **13**, 581-583 (2016).
- 805 47. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq
806 data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 807 48. Kursa, M.B. & Rudnicki, W.R. Feature Selection with the Boruta Package. *2010* **36**, 13 (2010).
- 808 49. Barbie, D.A., *et al.* Systematic RNA interference reveals that oncogenic KRAS-driven cancers require
809 TBK1. *Nature* **462**, 108-112 (2009).
- 810 50. Liberzon, A., *et al.* The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst*
811 **1**, 417-425 (2015).
- 812

813
814


815 **Supplementary Figures**

Actinobacteria, Kruskal–Wallis test
(Pre–Abundance ~ Domination), $p=0.0576$



816 **Supplementary Figure S1:** Pretreatment abundance of Phylum Actinobacteria predicts post-treatment
817 domination status ($p=0.0576$).
818
819

Bacilli, Kruskal–Wallis test (Pre-Abundance ~ Domination), $p=0.0326$





820

821

Supplementary Figure S2: Pretreatment abundance of Class Bacilli predicts post-treatment domination status ($p=0.0326$).

823



824

825

826

827

828


829

830

Supplementary Figure S3. A. Receiver operating characteristic (ROC) curves with confidence intervals for random forests and support vector machines generated through comparison of microbiome data and peripheral RNAseq gene expression data for volunteers before treatment and after 14 days of either HRZE or NTZ therapy. Solid lines indicate the true comparison, and dotted lines indicate random (scrambled) labels. **B.** PCA plot of RNAseq peripheral gene expression comparing pretreatment samples randomized to either NTZ or HRZE.

831

832



833

834

835


836

837

838

839

Supplementary Figure S4. Summary of Random Forest Regression results for all differentially expressed transcripts between pretreatment/posttreatment samples (not just those previously associated with active TB) that were found significantly affected by HRZE or NTZ (See Methods). Frequency indicates the ratio between the number of times a predictor is found to be significantly important in predicting gene abundance over the total number of surveyed genes.



840

841

842

843


844

845

846

847

Supplementary Figure S5. Application of linear mixed effect modeling to predict the abundance of transcripts that are found to be significantly affected by TB bacterial load as measured by TTP in the NTZ cohort as a function of NTZ and by using patient ID as random effect. Even though NTZ does not affect TTP, variability in change in TTP for these individuals is found to explain changes in expression for several host genes previously associated with active TB. The y axis shows the change in each gene's expression from 0 to 14 days, and the x axis shows the change in TTP across that same time.



848

849

850

851


852

853

854

855

Supplementary Figure S6: Peripheral gene expression changes in HRZE and NTZ treated groups. A. Top 10 predictors of gene expression change in the HRZE cohort. Bacterial load (TTP) is the primary quantity that predicts the change in gene expression for almost three quarters of the genes that change in the HRZE cohort, with significant contributions of Clostridia. **B.** Top 10 predictors of gene expression change in the NTZ cohort. Change in abundance of *Gemmiger formicilis* is the primary quantity that predicts change in gene expression in the NTZ cohort. **C.** Scaled relative abundance of the top predictors and the genes that are significantly altered for HRZE. **D.** Scaled relative abundance of the top predictors and the genes that are significantly altered for NTZ.



856

857

Supplementary Figure S7: Within-sample GSEA analysis (ssGSEA) of common TB pathways from the R package TBSignatureProfiler. These pathways represent well validated gene lists that predict active TB from LTBI progression, and were the inputs used to generate the meta-signature in the primary analysis of this paper ¹⁷.

858

859

860